The clinical availability of new pharmacological agents also offers other options, although in some cases the use of these drugs is limited, at least for the moment, to very restricted cohorts of patients. Examples of these drugs are microsomal triglyceride transfer protein inhibitors, like lomitapide, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, cholesterol ester transfer protein inhibitors and several others still in the industry pipeline [49]